Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 464Lung Neoplasms 147Melanoma 92Squamous Cell Carcinoma of Head and Neck 70Carcinoma, Renal Cell 63Neoplasms 61Colorectal Neoplasms 61Triple Negative Breast Neoplasms 48Neoplasm Metastasis 48Parkinson Disease 4, Autosomal Dominant Lewy Body 44Ovarian Neoplasms 42Stomach Neoplasms 39Small Cell Lung Carcinoma 39Pancreatic Neoplasms 39Carcinoma, Transitional Cell 38Breast Neoplasms 38Head and Neck Neoplasms 34Uterine Cervical Neoplasms 30Endometrial Neoplasms 30Urinary Bladder Neoplasms 26Esophageal Neoplasms 24Carcinoma, Hepatocellular 24Mesothelioma 21Mesothelioma, Malignant 18Kidney Neoplasms 15Prostatic Neoplasms 14Adenocarcinoma of Lung 14Carcinoma 13Colonic Neoplasms 12Cholangiocarcinoma 12

Interventions

Etoposide 3Carboplatin 3Paclitaxel 2sintilimab 1pembrolizumab 1olaparib 1ceralasertib 1atezolizumab 1apatinib 1anlotinib 1Topotecan 1Platinum 1Immune Checkpoint Inhibitors 1Drug Therapy 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
SCLC × pembrolizumab × Thoracic × Clear all
NCT04677361 2021-10-08

Feasibility Study on Expandion of MILs From NSCLC and SCLC Patients and Infusion With Pembrolizumab

Fox Chase Cancer Center

Phase EARLY_PHASE1 Withdrawn
Thoracic

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡